@article{e0460e10030d44578c69d8c029cd0ac2,
title = "Targeting cancer{\textquoteright}s sweet spot: UGP2 as a therapeutic vulnerability",
abstract = "Understanding the mechanisms governing metabolic reprogramming that underlie potential vulnerabilities in cancer cells is key to developing novel therapeutic strategies. The catalytic enzyme UDP-glucose pyrophosphorylase 2 (UGP2) drives the production of UDP-glucose. Our recent work demonstrated the crucial role of UGP2 in cancer growth and its regulation of cellular metabolic processes.",
keywords = "UDP-glucose, UGP2, YAP, cancer metabolism, glycosylation",
author = "Sunghoon Kim and Andrew Wolfe and Kim, {Sung Eun}",
note = "Funding Information: A.L.W. received research funding from Oncogenuity, Inc. for an unrelated project. Funding Information: A.L.W. was a Damon Runyon Fellow, supported by the Damon Runyon Cancer Research Foundation through postdoctoral fellowship number DRG-2214-15. The research reported in this publication was supported by the National Cancer Institute of the NIH under Award K99CA226363 and R00CA226363 (to A.L.W.) and the National Research Foundation of Korea Grant NRF-2020R1C1C1013220 (to S.E.K.). We would like to thank Dr. Frank McCormick for support and guidance. Thanks to Avrosina Kamel and Ariel Liberchuk for reading the draft manuscript. Some results mentioned here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga, the DepMap portal http://depmap.org/, and pantherdb gene ontology software. Publisher Copyright: {\textcopyright} 2021 Taylor & Francis Group, LLC.",
year = "2021",
doi = "10.1080/23723556.2021.1990676",
language = "English",
volume = "8",
journal = "Molecular and Cellular Oncology",
issn = "2372-3556",
publisher = "Taylor and Francis Ltd.",
number = "6",
}
